SML0218
Bropirimine
≥98% (HPLC)
Synonym(s):
2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone, NSC 149027, PNU 54461, U 54461, U 54461S
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C10H8BrN3O
CAS Number:
Molecular Weight:
266.09
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)
SMILES string
NC1=NC(=O)C(Br)=C(N1)c2ccccc2
InChI key
CIUUIPMOFZIWIZ-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: ≥5 mg/mL (warm DMSO)
storage temp.
room temp
Quality Level
Application
Bropirimine, an immunostimulating agent and toll like receptor (TLR7) agonist, is used in comparison with other TLR7 agonists such as imiquimod, R-848, loxoribine in interferon cell signaling research. Bropirimine may be used in experimental autoimmune encephalomyelitis (EAE) and bladder cancer research.
Biochem/physiol Actions
Bropirimine is an immunostimulant, anti-tumor agent
Bropirimine is an immunostimulating agent. The compound induces production of α and β interferons and enhances NK cell function. Bropirimine has antiproliferative effects in cancer cell lines and tumor growth in in vivo models.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
G Lievano et al.
Methods and findings in experimental and clinical pharmacology, 19(4), 261-267 (1997-05-01)
The role of bropirimine in prostate cancer remains unexplored. To address the efficacy of this immune modulator as neoadjuvant therapy we utilized the orthotopic placement of the Dunning AT-3 tumor. 2.4-2.6 x 10(6) Dunning AT-3 cells were injected into the
U O Nseyo et al.
Seminars in surgical oncology, 13(5), 342-349 (1997-09-01)
Intravesical therapy has been used in the management of superficial transitional cell carcinoma (TCC) of the urinary bladder (i.e., Ta, Tl, and carcinoma in situ) with specific objectives which include treating existing/residual tumor, preventing recurrence of tumor, preventing disease progression
W P Witjes et al.
European urology, 36(6), 576-581 (1999-11-24)
This European phase III clinical trial was part of an intercontinental study which was closed prematurely by the sponsor. The study was designed to compare the effects of oral bropirimine with intravesical BCG, the current standard treatment in patients with
Masa Bosnjak et al.
The Journal of membrane biology, 251(2), 179-185 (2017-02-17)
Gene electrotransfer upregulate DNA pattern recognition receptors or DNA sensors, which are part of the innate immune system. In this study, we tested if addition of the cocktail of innate immune system inhibitors to the cells during gene electrotransfer (GET)
M Echezarreta-López et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 9(4), 381-386 (2000-02-09)
Bropirimine (ABPP) is an orally active immunomodulator that increases endogenous alpha-interferon and other cytokines used clinically against carcinoma in situ of the bladder. The oral absorption of ABPP is poor because its low solubility in water. The purpose of this
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service